FGFR2 and breast carcinoma: A notable candidate is formononetin, an isoflavonoid from Astragalus membranaceus and Astragalus mongholicus, with anti-angiogenic and anti-cancer activities that suppresses FGF2-triggered activation of FGFR2 and Akt signaling, in both breast cancer cells and a xenograft model of breast cancer, and enhances the effect of the VEGFR2 inhibitor, sunitinib, on tumor growth inhibition (Wu et al., 2015).